

February 19, 2026



# Definium Therapeutics to Report Full Year 2025 Financial Results on February 26, 2026

NEW YORK--(BUSINESS WIRE)-- Definium Therapeutics, Inc. (formerly Mind Medicine (MindMed) Inc.), (NASDAQ: DFTX), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced that it will host a live webcast at 4:30 p.m. EST on Thursday, February 26, 2026 to report financial results for the full year ended December 31, 2025, and discuss recent business updates.

Listeners can register for the webcast via this [link](#). Analysts wishing to participate in the question and answer session should use this [link](#). A replay of the webcast will be available via the Investor Relations section of the Definium Therapeutics website, [ir.definiumtx.com](http://ir.definiumtx.com), and archived for at least 30 days after the webcast. Those who plan on participating are advised to join 15 minutes prior to the start time.

## About Definium Therapeutics

The mission of Definium Therapeutics is to forge a new era of psychiatry by applying scientific rigor to psychedelics, with the goal of developing accessible treatments that unlock healing at scale. Guided by a recognition that patients deserve more than better, Definium is relentlessly advancing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders. By turning evidence into impact, Definium aims to change the trajectory of today's mental health care crisis and enable a healthier future. Headquartered in New York, Definium Therapeutics trades on Nasdaq under the symbol DFTX.

For more information, visit <https://definiumtx.com/> and follow Definium Therapeutics on [Instagram](#), [LinkedIn](#) and [X](#).

View source version on businesswire.com:

<https://www.businesswire.com/news/home/20260219692160/en/>

## Investor Contact:

Gitanjali Jain  
VP, Head of Investor Relations  
[IR@definiumtx.com](mailto:IR@definiumtx.com)

## Media Contact:

[media@definiumtx.com](mailto:media@definiumtx.com)

Source: Definium Therapeutics, Inc.